Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non …
U Batra, B Biswas, K Prabhash… - BMJ open respiratory …, 2023 - bmjopenrespres.bmj.com
The most common oncogenic driver in non-small-cell lung cancer (NSCLC) is the epidermal
growth factor receptor (EGFR) gene mutations that occur more frequently among Asians …
growth factor receptor (EGFR) gene mutations that occur more frequently among Asians …
Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers (lung-molGPA)
C Nieder, M Hintz, O Oehlke, A Bilger, AL Grosu - Radiation oncology, 2017 - Springer
Background Many patients with brain metastases from non-small cell lung cancer have
limited survival, while others survive for several years, depending on patterns of spread …
limited survival, while others survive for several years, depending on patterns of spread …
The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis
Previous studies have demonstrated the association between EGFR mutations and distant
metastasis. However, the association for subsequent brain metastasis (BM) in stages I-III …
metastasis. However, the association for subsequent brain metastasis (BM) in stages I-III …
Development and validation of a novel survival prediction model in patients with spinal metastasis from non-small cell lung cancer
M Yang, W Xu, T Liu, X Yang, P Wang, S Wu, H Wei… - Spine, 2019 - journals.lww.com
Study Design. Retrospective study. Objective. The aim of this study was to develop a model
for predicting survival of patients with non-small cell lung cancer (NSCLC) spinal metastasis …
for predicting survival of patients with non-small cell lung cancer (NSCLC) spinal metastasis …
[HTML][HTML] Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching …
M Zhuo, Q Zheng, J Zhao, M Wu, T An… - Chinese Journal of …, 2017 - ncbi.nlm.nih.gov
Objective Although superior clinical benefits of epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer …
tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer …
Transformation to small‑cell lung cancer following treatment with icotinib in a patient with lung adenocarcinoma
H Lu, B Chen, J Qin, F Xie, N Han… - Oncology …, 2018 - spandidos-publications.com
The present study describes the case of a 48-year-old man who was diagnosed with lung
adenocarcinoma with an epidermal growth factor receptor (EGFR) 21 L858R mutation. The …
adenocarcinoma with an epidermal growth factor receptor (EGFR) 21 L858R mutation. The …
Role of epidermal growth factor receptor-tyrosine kinase inhibitors in the management of central nervous system metastases in epidermal growth factor receptor …
U Batra, N Lokeshwar, S Gupta… - Indian Journal of …, 2017 - journals.lww.com
Metastases to central nervous system (CNS) are very common in nonsmall cell lung cancer
(NSCLC) patients with epidermal growth factor receptor (EGFR)-positive mutation. Brain is …
(NSCLC) patients with epidermal growth factor receptor (EGFR)-positive mutation. Brain is …
[PDF][PDF] 非小细胞肺癌EGFR 基因不同突变位点对TKI 治疗反应的meta 分析
柯张延， 张志红， 张妍蓓， 宁雅静， 徐珂 - 安徽医科大学学报, 2019 - aydxb.cn
摘要目的比较表皮生长因子受体(EGFR) 中外显子19 缺失和外显子21 L858R
替换两个突变位点对酪氨酸激酶抑制剂(TKI) 的反应. 方法以“NSCLC”“non-small cell lung …
替换两个突变位点对酪氨酸激酶抑制剂(TKI) 的反应. 方法以“NSCLC”“non-small cell lung …
[HTML][HTML] 深圳市164 例非小细胞肺癌EGFR 突变分析
洪永忠， 陈延伟， 艾文， 巫翠华， 梁巧媚， 金虹… - 武汉大学学报(医学 …, 2018 - xml-data.org
目的: 探讨深圳市164 例非小细胞肺癌患者组织样本中表皮生长因子受体(EGFR)
基因的突变情况. 方法: 采用华因康Pstar-ⅡA 基因测序仪, 基于边连接边测序的DNA …
基因的突变情况. 方法: 采用华因康Pstar-ⅡA 基因测序仪, 基于边连接边测序的DNA …
[HTML][HTML] Determination of mutations (del E746-A750 exon 19 and L858R exon 21) in the epidermal growth factor receptor (EGFR) gene in serum samples and in …
K Castro-Valencia, L González-Herrera… - Revista …, 2018 - medigraphic.com
Introduction. EGFR mutations, del E746-A750 in exon 19 and L858R in exon 21 in tumor
cells of NMLC represent biomarkers of response to tyrosine kinase inhibitors (TKI) therapy …
cells of NMLC represent biomarkers of response to tyrosine kinase inhibitors (TKI) therapy …